A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

Not specified

Conditions
HIV InfectionsHIV Wasting Syndrome
Interventions
DRUG

Thalidomide

Trial Locations (13)

10021

Rockefeller Univ, New York

19107

Thomas Jefferson Med College, Philadelphia

20037

George Washington Univ Med Ctr, Washington D.C.

33146

Community Research Initiative of South Florida, Coral Gables

64111

Kansas City AIDS Research Consortium, Kansas City

91403

Gottlieb Med Group, Sherman Oaks

94110

San Francisco Gen Hosp, San Francisco

94115

Kaiser Permanente Med Ctr, San Francisco

94904

Marin County Specialty Clinic, Greenbrae

921038681

UCSD Med Ctr - Owen Clinic, San Diego

940631633

AIDS Community Research Consortium, Redwood City

981225314

Advanced Research Management, Seattle

07102

Saint Michael's Med Ctr, Newark

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT00002127 - A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome | Biotech Hunter | Biotech Hunter